Evidation Advances First-of-Its-Kind Flare-Triggered Proteomics Approach for Autoimmune Research

PACE pilot combines fully decentralized molecular sampling with longitudinal health data, laying the groundwork for new multimodal datasets to help researchers better understand disease mechanisms, identify potential drug targets, and develop more sophisticated models of immune-system activity.

SAN MATEO, Calif.--(BUSINESS WIRE)--Evidation, the leader in direct-from-participant real-world data and health research, today announced the completion of participant monitoring and biospecimen collection in its Precision in Autoimmune Condition Evidence (PACE) pilot, advancing a new approach to understanding the biology of autoimmune disease as it changes over time.

PACE is the first study of its kind in rheumatoid arthritis to combine fully decentralized, symptom-triggered blood collection across baseline, flare, and recovery states with longitudinal symptom reports, wearable measurements, and clinical history. By bringing these data sources together, the approach creates a new picture of autoimmune disease as it unfolds in everyday life, offering researchers a deeper understanding of the biological changes that accompany flares and recovery.

Designed as an initial pilot, PACE evaluated the feasibility of this sampling and data-linkage approach, with exploratory analyses planned to examine within-person changes in 251 inflammation-associated proteins across baseline, flare, and recovery states. Over approximately 60 days, 29 study participants contributed more than 1,300 daily symptom assessments that informed the timing of at-home blood collection. The study also included baseline genetic sampling.

PACE builds on Evidation's temporal proteomics platform, introduced in January 2026, with participants recruited from the company's autoimmune research cohort. Launched in November 2025, the cohort engages individuals living with autoimmune conditions through daily flare assessments, periodic surveys, and linked wearable and clinical data. Built on Evidation's direct, ongoing relationships with more than 100,000 individuals diagnosed with autoimmune conditions, the cohort provides a foundation for expanding event-triggered molecular sampling beyond the initial pilot. As of October 2026:

• More than 4,400 individuals are currently participating in the cohort across conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Sjögren’s disease, inflammatory bowel disease, and multiple sclerosis, contributing longitudinal data on symptoms, treatments, and disease impact.
• More than 3,200 participants have completed at least 30 daily flare assessments, and more than 1,500 have reported at least one qualifying flare episode, with detailed symptom data captured during those episodes.
• More than 1,200 individuals have wearable observations around reported flare episodes, with a subset having linked electronic health records, enabling researchers to examine changes in symptoms and physiology alongside clinical history.

“Some of the most important changes in autoimmune disease happen between clinical visits, when researchers rarely capture biological data alongside detailed symptoms,” said Leslie Oley Wilberforce, CEO of Evidation. “Our ambition is to bring those moments into view by connecting molecular biology with how disease unfolds in people’s daily lives, at scale. PACE is creating a first-of-its-kind view of the biological changes surrounding rheumatoid arthritis flares and recovery. We're excited to expand this work across our growing autoimmune cohort to build a differentiated resource that advances the development of new treatments for autoimmune disease.”

Evidation will share more about its autoimmune research platform during Fierce Biotech at London Life Sciences Week on November 17, 2026, in London, where Chief Medical Officer Sunny Khan, MPH, MBChB, MRCGP, will be speaking.

Life sciences partners interested in exploring potential collaboration can contact [e-mail].

About Evidation

Evidation is redefining real-world data through direct, interactive relationships with millions of individuals. Through continuous engagement, Evidation captures longitudinal data to provide a more complete picture of health, including patient-reported and functional outcomes, connected device data, permissioned clinical records, and biosamples. Its privacy-first platform supports a right person, right time approach to data collection, enabling faster research, stronger evidence, and better product decisions. Founded in 2012, Evidation is headquartered in California.